Key regions: Germany, United States, France, China, Canada
The Anti-Hypertensive Drugs market in United Arab Emirates has been growing steadily over the years, with an increasing demand for these drugs due to the rising prevalence of hypertension in the country.
Customer preferences: Customers in the UAE have shown a preference for branded drugs over generic ones, as they perceive them to be of higher quality and more effective. This preference for branded drugs has resulted in a higher market share for multinational pharmaceutical companies operating in the country.
Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in the UAE is the increasing availability of combination drugs. These drugs combine two or more active ingredients in a single pill, making it more convenient for patients to take their medication. Combination drugs have been found to be more effective in controlling blood pressure than single drugs, leading to an increase in their demand.Another trend in the market is the growing adoption of telemedicine services. With the COVID-19 pandemic, there has been a shift towards remote consultations and telemedicine services, which has made it easier for patients to access healthcare services. This has also increased the demand for home delivery of medications, including Anti-Hypertensive Drugs.
Local special circumstances: The UAE has a high prevalence of hypertension, with around 30% of the population suffering from the condition. This has led to an increasing demand for Anti-Hypertensive Drugs in the country. Additionally, the UAE has a large expatriate population, which has also contributed to the growth of the market.
Underlying macroeconomic factors: The healthcare sector in the UAE is heavily influenced by government policies and initiatives. The government has been investing heavily in healthcare infrastructure, which has led to an increase in the availability of healthcare services in the country. Additionally, the UAE has a high per capita income, which has led to an increase in healthcare spending. These factors have contributed to the growth of the Anti-Hypertensive Drugs market in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
